Tecfidera

Mylan, looking to capitalize on Biogen's Tecfidera patent loss, faces fork in the road on generic launch
Mylan, looking to capitalize on Biogen's Tecfidera patent loss, faces fork in the road on generic launch
Fierce Pharma
Biogen
Tecfidera
Mylan
patents
generics
MS
multiple sclerosis
Flag link:
Judge wipes out Biogen's Tecfidera patent protections in suit against Mylan
Judge wipes out Biogen's Tecfidera patent protections in suit against Mylan
Fierce Pharma
Biogen
Mylan
Tecfidera
patents
MS
multiple sclerosis
Flag link:
Will Biogen’s Big Patent Victory Ease Investor Worries About Its Alzheimer’s Drug?
Will Biogen’s Big Patent Victory Ease Investor Worries About Its Alzheimer’s Drug?
Motley Fool
Biogen
Mylan
Alzheimer's disease
patents
Tecfidera
MS
multiple sclerosis
Vumerity
Flag link:
Biogen wins Tecfidera patent challenge from Mylan, sending shares way up
Biogen wins Tecfidera patent challenge from Mylan, sending shares way up
Fierce Pharma
Biogen
patents
Tecfidera
Mylan
multiple sclerosis
MS
Flag link:
Why Biogen's Recent Rebound May Not Last -- at Least for Now
Why Biogen's Recent Rebound May Not Last -- at Least for Now
Motley Fool
Biogen
MS
multiple sclerois
Alzheimer's disease
Tecfidera
aducanumab
Flag link:
Vumerity’s $88,000 List Price Not What ‘We Had Hoped,’ National MS Society Says
Vumerity’s $88,000 List Price Not What ‘We Had Hoped,’ National MS Society Says
Multiple Sclerosis News Today
Biogen
MS
multiple sclerosis
Vumerity
drug pricing
Tecfidera
Flag link:
A new company enters the Tecfidera fight, offering to kill two birds
A new company enters the Tecfidera fight, offering to kill two birds
Endpoints
Biogen
Tecfidera
MS
flushing
Vitalis Pharmaceuticals
Flag link:
Biogen, wrestling MS rivals, touts 10 year-plus Tecfidera data
Biogen, wrestling MS rivals, touts 10 year-plus Tecfidera data
Fierce Pharma
Biogen
Tecfidera
MS
multiple sclerosis
Flag link:
Biogen beats estimates on multiple sclerosis therapy sales Reuters
Biogen beats estimates on multiple sclerosis therapy sales Reuters
Yahoo/Reuters
Biogen
earnings
Tecfidera
Flag link:
Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Endpoints
Biogen
MS
multiple sclerosis
Tecfidera
ALKS 8700
Vumerity
Alkermes
Flag link:
Upcoming events – key tests approach for Biogen and Kalvista
Upcoming events – key tests approach for Biogen and Kalvista
EP Vantage
Biogen
BIIB098
Tecfidera
multiple sclerosis
KalVista
HAE
Biocryst
BCX7353
KVD900
Flag link:
After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge
After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge
EP Vantage
Biogen
Alzheimer's disease
Tecfidera
generics
Mylan
Flag link:
14 Drugs Earn Billions for These Massachusetts Biotechs
14 Drugs Earn Billions for These Massachusetts Biotechs
BioSpace
Massachusetts
Boston
Biogen
Tecfidera
Benepali
Shire
Takeda
Vyvanse
Vertex Pharmaceuticals
Orkambi
Kalydeco
Alexion
Soliris
Strensiq
Sanofi Genzyme
Lantus
Ironwood Pharmaceuticals
Linzess
Flag link:
New insight into how Biogen's Tecfidera works may lead to better MS therapies
New insight into how Biogen's Tecfidera works may lead to better MS therapies
Fierce Biotech
Biogen
Tecfidera
MS
multiple sclerois
R&D
Flag link:
Mylan takes step toward knocking down key patent for Biogen's top-seller
Mylan takes step toward knocking down key patent for Biogen's top-seller
Biopharma Dive
Mylan
Biogen
Tecfidera
patents
inter partes review
Flag link:
Forward Pharma loses appeal in Tecfidera patent dispute with Biogen
Forward Pharma loses appeal in Tecfidera patent dispute with Biogen
Reuters
Biogen
Tecfidera
MS
Forward Pharma
Flag link:
What's beyond hepatitis C in the drug launch hit parade? Ibrance and Tecfidera, for two
What's beyond hepatitis C in the drug launch hit parade? Ibrance and Tecfidera, for two
Fierce Pharma
drug launches
hepatitis C
Ibrance
Tecfidera
Biogen
Pfizer
Gilead Sciences
Flag link:
How Biogen Inc. Makes Most of Its Money
How Biogen Inc. Makes Most of Its Money
Motley Fool
Biogen
Tecfidera
Tysabri
MS
multiple sclerosis
Flag link:
Biogen aims to block Tecfidera generics with flurry of lawsuits
Biogen aims to block Tecfidera generics with flurry of lawsuits
Bizjournals.com
Biogen
Tecfidera
generics
MS
multiple sclerosis
Novartis
Sandoz
Mylan Labs
Flag link:
Why Roche's New Drug Is Bad News For Biogen
Why Roche's New Drug Is Bad News For Biogen
Barron's
Roche
Biogen
Ocrevus
multiple sclerosis
MS
Tysabri
Tecfidera
Flag link:

Pages